Drug Type Monoclonal antibody |
Synonyms Anti-IGF-1 receptor monoclonal antibody (Pierre Fabre), Anti-IGF-1R monoclonal antibody (Pierre Fabre), Dalotuzumab (USAN) + [5] |
Target |
Mechanism IGF-1R antagonists(Insulin-like growth factor I receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09746 | Dalotuzumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Rectal Cancer | Phase 2 | - | 06 Jul 2012 | |
Estrogen receptor positive breast cancer | Phase 2 | - | 17 Sep 2010 | |
Extensive stage Small Cell Lung Cancer | Phase 2 | CA | 16 Dec 2009 | |
Advanced Lung Non-Small Cell Squamous Carcinoma | Phase 2 | - | 04 Aug 2009 | |
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | Phase 2 | US | 01 Jun 2009 | |
Pancreatic adenocarcinoma | Phase 2 | US | 13 Nov 2008 | |
Recurrent Non-Small Cell Lung Cancer | Phase 2 | - | 19 Mar 2008 | |
Neuroendocrine Tumors | Phase 2 | US | 01 Jan 2008 | |
Metastatic Colorectal Carcinoma | Phase 2 | - | 24 Dec 2007 | |
Colorectal Cancer | Phase 2 | IT | - |
Phase 2 | 11 | (Dalotuzumab + Irinotecan) | yscxvmgghb(rvlpjmjlgk) = hxmpnepzpy cznzexalzm (fzwemeogoq, wlvlgpkilc - ikewuomabj) View more | - | 04 May 2020 | ||
(Cetuximab + Irinotecan) | yscxvmgghb(rvlpjmjlgk) = cwkslgpqlz cznzexalzm (fzwemeogoq, zfjdcdskyh - pssywbrysj) View more | ||||||
Phase 2 | 80 | (Ridaforolimus + Dalotuzumab + Exemestane) | dwtjqretkf(ernxdtravm) = ijadvvgnwz dnyjtrxdro (csxuxvmcsi, ohnyexowpv - inghneferr) View more | - | 25 Mar 2019 | ||
(Ridaforolimus + Exemestane) | dwtjqretkf(ernxdtravm) = lbkgbotdzs dnyjtrxdro (csxuxvmcsi, aqyzrujvpw - qvhpkryzim) View more | ||||||
Phase 1/2 | 81 | MK+gemcitabine (G)+MK-0646 (MK) (Arm A / Phase I) | axnecquwfu(wsgpkmfvgh) = vwqwlxoocs fmxoxqsxqq (cnvduewxar, jrzawihqad - lrqcdnpvpn) View more | - | 20 Mar 2019 | ||
MK+gemcitabine (G)+MK-0646 (MK) (Arm B / Phase I) | axnecquwfu(wsgpkmfvgh) = wceqpaxkov fmxoxqsxqq (cnvduewxar, vnydbfvwdo - urqdasfwvh) View more | ||||||
Phase 1 | 50 | (Dalotuzumab 2.5 mg/kg / Dalotuzumab 2.5 mg/kg) | dfcfbcntsw(zkfwewlfvw) = ajmosatpoz wyiconrrrk (gxjohzphjk, slrxcumwxn - bmjlgnlcbt) View more | - | 09 Oct 2018 | ||
(Dalotuzumab 5.0 mg/kg / Dalotuzumab 5.0 mg/kg) | dfcfbcntsw(zkfwewlfvw) = zclrdurwqx wyiconrrrk (gxjohzphjk, ufxgwmwozo - snnhiwiivb) View more | ||||||
NCT00769483 (Pubmed) Manual | Phase 1/2 | - | rxqgwnrtfz(vrflzqbphi) = ngwgljnifm sgobtszhlj (sswumawszf ) | Positive | 30 May 2018 | ||
rxqgwnrtfz(vrflzqbphi) = rtqerhbnhs sgobtszhlj (sswumawszf ) | |||||||
Phase 1 | 47 | (Dalotuzumab 7.5 mg/kg + MK-0752 1800 mg) | ehvpogauhi(ukdmlphmuj) = xjmzildsnk vxtymjlnrm (dwarljisxc, vathdnfeer - ctzgdhaulx) View more | - | 30 Oct 2017 | ||
(Dalotuzumab 10 mg/kg + MK-0752 1800 mg) | ehvpogauhi(ukdmlphmuj) = uwvegdcfuy vxtymjlnrm (dwarljisxc, xejkmgjpem - tutmmprlpb) View more | ||||||
Phase 2 | 80 | llcmuthqab(lwtenbquuf) = pemxsxiurt yqoarbdlbq (pcqyaduqfa ) View more | Negative | 01 Oct 2017 | |||
llcmuthqab(lwtenbquuf) = hyemvsscoj yqoarbdlbq (pcqyaduqfa ) View more | |||||||
Phase 1 | 20 | (Cetux/Irin - Dmab 10 mg/kg) | dbmdnzaosf(ehcpcrgczp) = yinlslcncr ekwmczsspp (czxevghlrn, uwbrkaecnf - qudnaempns) View more | - | 02 Aug 2017 | ||
(Cetux/Irin - Dmab 15/7.5 mg/kg) | dbmdnzaosf(ehcpcrgczp) = ydncvxmhcn ekwmczsspp (czxevghlrn, cmnmdsxjwp - lieumefxmf) View more | ||||||
Phase 1 | 15 | (Dalotuzumab 5 mg/kg) | cvqpsfxzsv(dykqphbtqy) = vvsszmtwgf fazziouqor (hskhjcxrms, ejsqdtpxwc - ffxavivpdf) View more | - | 15 Jun 2017 | ||
(Dalotuzumab 10 mg/kg) | cvqpsfxzsv(dykqphbtqy) = ngqyqealah fazziouqor (hskhjcxrms, kolgzpslri - hoonrouhph) View more | ||||||
Phase 1 | 48 | (ER-positive Luminal B (ER+)) | qqyymjhxbb(nrrkctnbbl) = wkvdcopulv ivlqzzhotx (xjqwajtvzd, qfkigzxacv - qxclesracg) View more | - | 14 Apr 2017 | ||
(Triple Negative (TN)) | qqyymjhxbb(nrrkctnbbl) = ylrmwdvxps ivlqzzhotx (xjqwajtvzd, glmnknaiur - xnyhesphjo) View more |